BriaCell Therapeutics Corp BCTX 深 滬
已收盤 01-09 16:00:00 美东时间
7.25
-0.030
-0.41%
華盛通- 最 高7.67
- 今 開7.64
- 成交量 4.73万股
- 最 低 7.00
- 昨 收 7.28
- 總市值 4912.67万
- 52周最高 98.20
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 6.00
- 委 比 93.55%
- 總股本 677.61万
- 歷史最高 1860.5799
- 量 比 0.48
- 振 幅 9.20%
- 歷史最低 6.88
- 每 手 1
- 風險率 16.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2...
01-07 23:32
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Trinity Biotech (NASDAQ:TRIB) stock moved upwards by 54.7% to $1.38 du...
2025-12-24 01:05
BriaCell Therapeutics Publishes Phase 3 Bria-IMT Clinical Study In Metastatic Breast Cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its
2025-12-18 20:34
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Braze Inc (NYSE:BRZE) rose sharply in pre-market trading after the co...
2025-12-10 18:00
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
BriaCell Therapeutics Corp. reported that its Phase 3 study for metastatic breast cancer (MBC) has screened over 230 patients and enrolled over 160. Enrollment is progressing well, with strong interest from clinical sites and patients. Topline interim data is expected in 1H2026, and the trial continues under FDA Fast Track designation. The study evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice in advanced MBC. Posi...
2025-12-09 12:30
BriaCell Therapeutics To Present Phase 2 Survival, And Phase 3 Biomarker Data Across Three Clinical Posters At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key
2025-12-02 20:39
BriaCell Therapeutics To Highlight Phase 2 Safety And Efficacy Signals And Biomarker Findings In Both Phase 2 And Pivotal Phase 3 Studies At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal
2025-11-25 20:37
BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that
2025-11-18 20:32
BriaCell To Present Preclinical Data On Next-Gen Cancer Vaccine Platform At SITC 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
2025-11-04 20:36
BriaCell Partners with MSK to Advance Cancer Immunotherapy
BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. BriaCell Therapeu...
2025-10-21 20:11
